The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Magnetic Resonance Imaging–Guided vs Computed Tomography–Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial
Open accessAbstract
Importance: Magnetic resonance imaging (MRI) guidance offers multiple theoretical advantages in the context of stereotactic body radiotherapy (SBRT) for prostate cancer. However, to our knowledge, these advantages have yet to be demonstrated in a randomized clinical trial. Objective: To determine whether aggressive margin reduction with MRI guidance significantly reduces acute grade 2 or greater genitourinary (GU) toxic effects after prostate SBRT compared with computed tomography (CT) guidance. Design, Setting, and Participants: This phase 3 randomized clinical trial (MRI-Guided Stereotactic Body Radiotherapy for Prostate Cancer [MIRAGE]) enrolled men aged 18 years or older who were receiving SBRT for clinically localized prostate adenocarcinoma at a single center between May 5, 2020, and October 1, 2021. Data were analyzed from January 15, 2021, through May 15, 2022. All patients had 3 months or more of follow-up. Interventions: Patients were randomized 1:1 to SBRT with CT guidance (control arm) or MRI guidance. Planning margins of 4 mm (CT arm) and 2 mm (MRI arm) were used to deliver 40 Gy in 5 fractions. Main Outcomes and Measures: The primary end point was the incidence of acute (≤90 days after SBRT) grade 2 or greater GU toxic effects (using Common Terminology Criteria for Adverse Events, version 4.03 [CTCAE v4.03]). Secondary outcomes included CTCAE v4.03–based gastrointestinal toxic effects and International Prostate Symptom Score (IPSS)–based and Expanded Prostate Cancer Index Composite-26 (EPIC-26)–based outcomes. Results: Between May 2020 and October 2021, 156 patients were randomized: 77 to CT (median age, 71 years [IQR, 67-77 years]) and 79 to MRI (median age, 71 years [IQR, 68-75 years]). A prespecified interim futility analysis conducted after 100 patients reached 90 or more days after SBRT was performed October 1, 2021, with the sample size reestimated to 154 patients. Thus, the trial was closed to accrual early. The incidence of acute grade 2 or greater GU toxic effects was significantly lower with MRI vs CT guidance (24.4% [95% CI, 15.4%-35.4%] vs 43.4% [95% CI, 32.1%-55.3%]; P = .01), as was the incidence of acute grade 2 or greater gastrointestinal toxic effects (0.0% [95% CI, 0.0%-4.6%] vs 10.5% [95% CI, 4.7%-19.7%]; P = .003). Magnetic resonance imaging guidance was associated with a significantly smaller percentage of patients with a 15-point or greater increase in IPSS at 1 month (6.8% [5 of 72] vs 19.4% [14 of 74]; P = .01) and a significantly reduced percentage of patients with a clinically significant (≥12-point) decrease in EPIC-26 bowel scores (25.0% [17 of 68] vs 50.0% [34 of 68]; P = .001) at 1 month. Conclusions and Relevance: In this randomized clinical trial, compared with CT-guidance, MRI-guided SBRT significantly reduced both moderate acute physician-scored toxic effects and decrements in patient-reported quality of life. Longer-term follow-up will confirm whether these notable benefits persist. Trial Registration: ClinicalTrials.gov Identifier: NCT04384770
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The American Urological Association Symptom Index for Benign Prostatic Hyperplasia
Barry, M. J., Fowler, F. J., O’Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., Cockett, A. T. K., & The Measurement Committee of the American Urological Association (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)36966-5 · Cited by 3,436
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
Donovan, J. L., Hamdy, F. C., Lane, J. A., Mason, M., Metcalfe, C., Walsh, E., Blazeby, J. M., Peters, T. J., Holding, P., Bonnington, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606221 · Cited by 1,338
Widmark, A., Gunnlaugsson, A., Beckman, L., Thellenberg-Karlsson, C., Hoyer, M., Lagerlund, M., Kindblom, J., Ginman, C., Johansson, B., Björnlinger, K., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31131-6 · Cited by 876
Soerjomataram, I., Lortet-Tieulent, J., Parkin, D. M., Ferlay, J., Mathers, C., Forman, D., & Bray, F. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60919-2 · Cited by 598
Brand, D. H., Tree, A. C., Ostler, P. J., van der Voet, H., Loblaw, A., Chu, W., Ford, D., Tolan, S. P., Jain, S., Martin, A. S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30569-8 · Cited by 572
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021: Featured Updates to the NCCN Guidelines
Schaeffer, E., Srinivas, S., Antonarakis, E. S., Armstrong, A. J., Bekelman, J. E., Cheng, H., D’Amico, A. V., Davis, B. J., Desai, N., Dorff, T., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0008 · Cited by 525
Szymanski, K. M., Wei, J. T., Dunn, R. L., & Sanda, M. G. (2010) · Urology · doi:10.1016/j.urology.2010.01.027 · Cited by 456
Michalski, J. M., Moughan, J., Purdy, J., Bosch, W., Bruner, D. W., Bahary, J.-P., Lau, H., Duclos, M., Parliament, M., Morton, G., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0039 · Cited by 356
Prostate cancer and health‐related quality of life: a review of the literature
Eton, D. T., & Lepore, S. J. (2002) · Psycho-Oncology · doi:10.1002/pon.572 · Cited by 346
Kishan, A. U., Dang, A. T., Katz, A. J., Mantz, C. A., Collins, S. P., Aghdam, N., Chu, F., Kaplan, I. D., Appelbaum, L., Fuller, D. B., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.8006 · Cited by 339
Self-citation
Cited by
Springer, F., Hambsch, P. K., Mehnert-Theuerkauf, A., & Nicolay, N. H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1546221 · Cited by 5
Metadata
- Authors
- Kishan, A. U., Ma, T. M., Lamb, J. M., Casado, M., Wilhalme, H., Low, D. A., Sheng, K., Sharma, S., Nickols, N. G., Pham, J., Yang, Y., Gao, Y., Neylon, J., Basehart, V., Cao, M., & Steinberg, M. L.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2023-03-01
- Volume
- 9
- Issue
- 3
- Pages
- 365
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W4315706058
- Cited by
- 323
- References
- 26
- FWCI
- 59.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Magnetic Resonance Imaging–Guided vs Computed Tomography–Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamaoncol.2022.6558
- The paper
- Kishan, A. U., Ma, T. M., Lamb, J. M., Casado, M., Wilhalme, H., Low, D. A., Sheng, K., Sharma, S., Nickols, N. G., Pham, J., Yang, Y., Gao, Y., Neylon, J., Basehart, V., Cao, M., & Steinberg, M. L. (2023). Magnetic Resonance Imaging–Guided vs Computed Tomography–Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2022.6558
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.